AU2004289098B2 - Use of an inhibitor of CSF-1 activity for the treatment of inflammatory bowel disease - Google Patents

Use of an inhibitor of CSF-1 activity for the treatment of inflammatory bowel disease Download PDF

Info

Publication number
AU2004289098B2
AU2004289098B2 AU2004289098A AU2004289098A AU2004289098B2 AU 2004289098 B2 AU2004289098 B2 AU 2004289098B2 AU 2004289098 A AU2004289098 A AU 2004289098A AU 2004289098 A AU2004289098 A AU 2004289098A AU 2004289098 B2 AU2004289098 B2 AU 2004289098B2
Authority
AU
Australia
Prior art keywords
csf
antibody
activity
polypeptide
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004289098A
Other languages
English (en)
Other versions
AU2004289098A1 (en
Inventor
Timothy Bourne
Alastair David Griffiths Lawson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Publication of AU2004289098A1 publication Critical patent/AU2004289098A1/en
Assigned to UCB PHARMA S.A. reassignment UCB PHARMA S.A. Request for Assignment Assignors: CELLTECH R&D LIMITED
Application granted granted Critical
Publication of AU2004289098B2 publication Critical patent/AU2004289098B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2004289098A 2003-11-05 2004-11-03 Use of an inhibitor of CSF-1 activity for the treatment of inflammatory bowel disease Ceased AU2004289098B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0325836.5 2003-11-05
GBGB0325836.5A GB0325836D0 (en) 2003-11-05 2003-11-05 Biological products
PCT/GB2004/004652 WO2005046657A2 (en) 2003-11-05 2004-11-03 Use of an inhibitor of csf-1 activity for the treatment of inflammatory bowel disease

Publications (2)

Publication Number Publication Date
AU2004289098A1 AU2004289098A1 (en) 2005-05-26
AU2004289098B2 true AU2004289098B2 (en) 2010-07-01

Family

ID=29725999

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004289098A Ceased AU2004289098B2 (en) 2003-11-05 2004-11-03 Use of an inhibitor of CSF-1 activity for the treatment of inflammatory bowel disease

Country Status (8)

Country Link
US (1) US20070148172A1 (enExample)
EP (1) EP1686970B1 (enExample)
JP (1) JP2007510639A (enExample)
AU (1) AU2004289098B2 (enExample)
CA (1) CA2543926A1 (enExample)
ES (1) ES2733818T3 (enExample)
GB (1) GB0325836D0 (enExample)
WO (1) WO2005046657A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009224955B2 (en) * 2008-03-14 2012-08-09 Transgene S.A. Antibody against the CSF-1 R
WO2010062399A2 (en) * 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
US8183207B2 (en) * 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
PT2949670T (pt) 2009-12-10 2019-05-20 Hoffmann La Roche Anticorpos que se ligam preferencialmente ao domínio extracelular 4 do csf1r e respetiva utilização
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
WO2011107553A1 (en) 2010-03-05 2011-09-09 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
CN107011438B (zh) * 2010-05-04 2020-11-20 戊瑞治疗有限公司 结合csf1r的抗体
AU2012285875B2 (en) 2011-07-18 2016-11-10 Morphosys Ag Use of c-Fms antagonists
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SG10201906328RA (en) 2012-08-31 2019-08-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN105121466A (zh) 2013-04-12 2015-12-02 莫佛塞斯公司 靶向m-csf的抗体
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
JP6964410B2 (ja) 2014-06-23 2021-11-10 ファイヴ プライム セラピューティクス インク コロニー刺激因子１受容体（ｃｓｆ１ｒ）に結合する抗体で疾患を治療する方法
LT3212670T (lt) 2014-10-29 2021-02-10 Five Prime Therapeutics, Inc. Kombinuotasis vėžio gydymas
ES2843586T3 (es) 2014-12-22 2021-07-19 Five Prime Therapeutics Inc Anticuerpos dirigidos contra CSF1R para tratar la SVNP
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
JP2018516933A (ja) * 2015-06-02 2018-06-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
EP3108897A1 (en) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
EP3504239B1 (en) 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
EP3558360A1 (en) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
KR20200051024A (ko) 2017-09-13 2020-05-12 파이브 프라임 테라퓨틱스, 인크. 췌장암에 대한 조합 항-csf1r 및 항-pd-1 항체 조합 요법
US20240269282A1 (en) 2021-05-10 2024-08-15 Institut Curie Methods for the Treatment of Cancer, Inflammatory Diseases and Autoimmune Diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932595A (en) * 1995-12-20 1999-08-03 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
WO1999043839A1 (en) * 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
WO2002087496A2 (en) * 2001-04-30 2002-11-07 Cedars-Sinai Medical Center Methods for inhibiting macrophage colony stimulating factor and c-fms-dependent cell signaling
WO2003020698A2 (en) * 2001-09-06 2003-03-13 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
AU2004275700A1 (en) * 2003-09-10 2005-04-07 Amgen Fremont Inc. Antibodies to M-CSF

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5780225A (en) * 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) * 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) * 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
WO1992018619A1 (en) * 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5807683A (en) * 1992-11-19 1998-09-15 Combichem, Inc. Combinatorial libraries and methods for their use
US5738996A (en) * 1994-06-15 1998-04-14 Pence, Inc. Combinational library composition and method
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) * 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
WO1999017798A1 (en) * 1997-10-02 1999-04-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
JP4307775B2 (ja) * 1999-10-28 2009-08-05 ゼイェトホサイン・アハリネヤート Ｃｓｆ−１インヒビターの使用
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US7381801B2 (en) * 2002-02-13 2008-06-03 Ludwig Institute For Cancer Research Chimerized GM-CSF antibodies
US6919483B2 (en) * 2003-05-23 2005-07-19 Mediquest Therapeutics, Inc. Immunomodulation with novel pharmaceutical compositions
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932595A (en) * 1995-12-20 1999-08-03 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
WO1999043839A1 (en) * 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
WO2002087496A2 (en) * 2001-04-30 2002-11-07 Cedars-Sinai Medical Center Methods for inhibiting macrophage colony stimulating factor and c-fms-dependent cell signaling
WO2003020698A2 (en) * 2001-09-06 2003-03-13 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
AU2004275700A1 (en) * 2003-09-10 2005-04-07 Amgen Fremont Inc. Antibodies to M-CSF

Also Published As

Publication number Publication date
US20070148172A1 (en) 2007-06-28
JP2007510639A (ja) 2007-04-26
CA2543926A1 (en) 2005-05-26
ES2733818T3 (es) 2019-12-03
WO2005046657A2 (en) 2005-05-26
AU2004289098A1 (en) 2005-05-26
EP1686970A2 (en) 2006-08-09
GB0325836D0 (en) 2003-12-10
EP1686970B1 (en) 2019-04-10
WO2005046657A3 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
AU2004289098B2 (en) Use of an inhibitor of CSF-1 activity for the treatment of inflammatory bowel disease
US7931900B2 (en) Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
US8304200B2 (en) Methods for obtaining antibodies
JP6618471B2 (ja) 線維性疾患の処置のための方法
TWI327070B (en) Modulators of p-selectin glycoprotein ligand 1
CA2402477A1 (en) Eosinophil-specific apoptosis inducer
CN119409833A (zh) 一种抗ceacam5和ceacam6双靶向抗体及其应用
CN118546246A (zh) 特异性结合il-8的抗体、抗体片段及其用途
US7771969B2 (en) Methods for obtaining antibodies
CN118546248A (zh) 特异性结合il-17a的抗体、抗体片段及其用途
CN118546249A (zh) 特异性结合TNF-α的抗体、抗体片段及其用途
HK40091184A (zh) 用於治疗纤维化疾病的方法

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: UCB PHARMA S.A.

Free format text: FORMER APPLICANT(S): CELLTECH R&D LIMITED

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired